Supernus to Present at the Jefferies Virtual Health Care Conference

Rhea-AI Summary

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced that its management will present an overview and update during the Jefferies Virtual Healthcare Conference on June 2, 2020, at 4:00 p.m. ET. Investors can arrange virtual meetings with management by contacting the conference coordinator. A live webcast of the presentation will be accessible on the company’s website, with a replay available for 60 days post-conference. Supernus focuses on CNS diseases and markets Trokendi XR® and Oxtellar XR® while developing products for ADHD, treatment-resistant depression, and epilepsy.

ROCKVILLE, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview and update, as well as host investor meetings, at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 4:00 p.m. ET. 

Investors interested in arranging a virtual meeting with the Company's management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of this webcast will be available for 60 days on the Company's website after the conference.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR^® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR^® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

CONTACTS:
Jack A. Khattar, President and CEO

Gregory S. Patrick, Senior Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo

Westwicke, an ICR Company

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

FAQ

When is Supernus Pharmaceuticals presenting at the Jefferies Virtual Healthcare Conference?

Supernus Pharmaceuticals will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 4:00 p.m. ET.

How can investors meet with Supernus Pharmaceuticals management during the conference?

Investors interested in virtual meetings with Supernus Pharmaceuticals management should contact the conference coordinator.

Where can I access the live webcast of Supernus Pharmaceuticals' presentation?

The live webcast of Supernus Pharmaceuticals' presentation can be accessed on their website in the Investor Relations section.

What products does Supernus Pharmaceuticals market?

Supernus Pharmaceuticals markets Trokendi XR® for migraine prophylaxis and epilepsy treatment, and Oxtellar XR® for epilepsy.

What new developments is Supernus Pharmaceuticals working on?

Supernus Pharmaceuticals is developing several product candidates, including SPN-812 for ADHD, SPN-820 for treatment-resistant depression, and SPN-817 for epilepsy.